Sophronepsis · Training sample

How to read a report

A guide to understanding Sophronepsis stock reports · It isn't about any company: it works for all of them.
This document is for training. It isn't a report on any specific company. It's the map so you know how to read the reports we produce: what each section contains, what it's for, and where people usually trip up when interpreting it. The same map works for any stock, sector or country.

A stock report can be intimidating at first — lots of numbers, jargon, columns. The good news: they all follow the same structure. Learn to read one, and you can read any. We'll go through, section by section, what you'll find inside. No rush.

1The header

It's the first line of the report. It contains: the company name, the ticker (the code it trades under — for example, three or four letters that represent it on the market), the sector (what it does: technology, health, energy…), the report date and who it's addressed to (your name, your reference).

What it's for: identifying without ambiguity. In a personal report every element counts — the ticker avoids confusion (there are companies with similar names listed in different countries), the date tells you whether the data is from today or from days ago, and your reference works as a watermark: the document is yours, it isn't shared.

2Current price and range for the year

You'll see something like: “Price 145.20 $ · 52-week range 98.40 – 168.50”.

The price is what one share is worth today. The 52-week range gives you quick context: where the price sits within the whole path of the last year. If it's right at the high, the stock has been rising strongly; if it's right at the low, it has been suffering; if it's in the middle, neither one nor the other.

The usual trap: thinking that “near the high” is a signal to buy (or sell). On its own, it isn't — it's just context. A stock can spend years making new highs, and another can sit at its low for a long time without recovering.

3Valuation multiples

You'll see terms like P/E, forward P/E and sometimes EV/EBITDA. They sound intimidating; they're simple.

P/E (price-to-earnings ratio): how many years it would take the company to pay you back what you pay for its share, if it kept its current earnings. A P/E of 20 means “20 years of today's earnings to pay for today's share”. The lower it is, the “cheaper” it looks — with nuances: there are sectors where a P/E of 8 is high and others where a P/E of 30 is normal.

Forward P/E: the same, but using the earnings EXPECTED next year (not the published ones). It's an estimate, not a fact. It can be wrong — it should always be marked as expected, not as actual.

EV/EBITDA: a “cleaner” multiple than P/E because it doesn't depend on the debt structure or on taxes. It's used to compare companies with different levels of debt. Below 10 is usually considered cheap; above 25, expensive.

What they're for: comparing. A P/E on its own, with nothing next to it, doesn't say much. Compared with the sector's average P/E, with the company's own historical P/E or with a direct competitor's P/E, it starts to speak.

4Dividend yield

You'll see something like: “Dividend 3.20% · payout 42%”.

The dividend (yield) is how much the company pays out to its shareholders each year, expressed as a percentage of the current price. 3.20% means that for every 100 € invested in the share, the company pays you back 3.20 € a year in cash.

The payout (payout ratio) is what percentage of the company's earnings goes to paying dividends. A 42% payout says: “of every 100 € the company earns, 42 € go to the shareholder and the rest is reinvested in the business”.

The usual trap: thinking a very high dividend is always good. A 12% yield is usually a warning sign, not an opportunity — either the price has fallen a lot (and the dividend hasn't adjusted yet), or the company is paying out more than it earns, and that dividend can't last. A payout above 90% is suspicious; above 100%, unsustainable.

5Balance sheet strength

Here you look at financial health. You'll see terms like debt / equity, current ratio and net margin.

Debt / equity: for every euro of the company's own capital, how much it owes. A ratio of 50% means “for every euro of its own, it has 0.50 € of debt” — comfortable. Above 200% it's considered heavily loaded; very high starts to be worrying in bad cycles.

Current ratio: whether it can pay its short-term debts. Above 1.5 is usually healthy; below 1, the company could get into trouble if something goes wrong in a quarter.

Net margin: of every 100 € it bills, how much turns into clean profit. A 20% margin is excellent (typical of technology); 4% is tight (typical of retail and banks). It depends on the sector.

6Growth

You'll see: revenue growth, ROE and sometimes expected earnings growth.

Revenue growth is how much sales have increased compared with the previous year. +8% is healthy; -3% is a sign to think things over (the market isn't rewarding the same thing).

ROE (return on equity): how much the company's own capital yields. It's like the business's internal interest rate. Above 15% is considered good; above 25% is excellent. Below 5%, the company isn't getting much out of its own money.

Expected growth is an estimate — it's calculated by comparing the current P/E with the forward P/E. If the P/E is going to fall, it's because earnings are expected to rise. It's a useful figure but, like any estimate, it can be wrong.

7The health score (/100)

You'll see a big number — for example 72 / 100 — with three bars underneath: valuation, balance sheet and growth.

It's an automatic summary of everything above, with a fixed and transparent criterion. The company earns points for each healthy metric and loses them for each weak one. The three pillars are worth roughly the same (33 points each).

What it's for: comparing stocks quickly without doing the maths. A stock with 72 is fundamentally more solid than one with 45. But it isn't a buy rating: a high score doesn't mean it will rise, and a low one doesn't mean it will fall. Prices move for many reasons unrelated to fundamentals. The score is a map for studying, not a verdict.

8The indicative valuation range

You'll see something like: “Indicative range (P/E 15 – 22): 120 $ – 175 $”.

It's calculated like this: we take the “reasonable” multiples for that company (based on its history and its sector) and apply them to current earnings. The result is the price range the company would have if it traded at the low end or the high end of those multiples.

It's useful context: if the market price is well below the range, technically the company looks undervalued (with nuances); if it's well above, technically it looks expensive.

The usual trap: thinking the range is a price target. It isn't. It's context. The multiples that “should” apply change with the cycle, with expectations, with the sector. The indicative range is a starting reference, not an infallible compass. And it is certainly not a recommendation to buy or sell.

9The written sections (5)

After the numbers, the report moves into prose reading. Five sections, with a fixed structure:

Summary: what the company does, in plain language. No industry jargon. In 3–5 sentences.

Valuation: what its multiples say today. Expensive, cheap, in line with its history. With nuances.

Balance sheet: strength. Whether its debt is manageable, whether it can withstand a bad year, whether it lives on cash or on credit.

Growth: how sales and expected earnings are evolving. What drivers it has.

Training follow-up: which 2 or 3 specific things are scheduled for the coming months. Results dates, milestones, pending decisions.

All sections are written on the same principle: describe, don't recommend. You'll never read “buy this share” or “it's an opportunity”. You will read “the price is below its historical range” or “debt has risen two years in a row”. The decision — always — is yours, with the data in front of you.

10The “worth a look” label

Sometimes you'll see a yellow notice above the stock like “worth a look” with a short reason: “results on 30-Jul”, “week of +9.4%”, “at 52-week lows”.

It's an automatic traffic light. It doesn't say something has to be done — it says there's an unusual circumstance there that affects how the stock is read. If its results come out on Thursday, any price move on Wednesday reads differently. If it has just lost 15% in five days, knowing why is more urgent than it was yesterday.

It's triggered by fixed criteria: results within the next 15 days, weekly moves > 5%, prices very close to the year's high or low.

11The “The numbers” table

At the end of the report you'll see a summary table with the hard data: price, 52-week range, current and forward P/E, dividend, EV/EBITDA, margin, ROE, debt / equity, revenue growth, next results.

It's the quick view for coming back to the report days later without rereading it all. If a figure is missing (for example, the company doesn't pay a dividend), it simply doesn't appear — we never make anything up.

12The report footer

You'll see the motto — “Wait. Observe. Execute.” — and the legal disclaimer. Both matter:

How to use a report when you receive it

Three useful readings, in this order:

  1. Quick read (2 min): health score + “The numbers” table + “worth a look” labels if any. With this you already know the stock's general situation.
  2. Medium read (10 min): the five written sections. That's where the considered reading is, without raw numbers.
  3. In-depth read (whenever you like): compare it with earlier reports on the same stock. Seeing how the multiples and the strength evolve quarter by quarter is what gives you your own judgement.

And one last thing: reports don't replace your decision. They're there so you decide with the data in front of you, not on hunches or out of fear. You'll never read “buy” or “sell” here. You will read “this is what there is”. With that, it's up to you.

To get started, take the investor profile test and we'll tell you where to go next.

Wait. Observe. Execute.
Sophronepsis · Training sample from the path · A document with no real data from any company: only the structure and the criteria used to build the real reports.
This is training. It is not financial advice or a recommendation to buy or sell. Once you're in, you'll receive real reports on your stocks in this same format and can request in-depth reports on demand.